Parasitology Research 2008-09-01

Imunomodulative effect of liposomized muramyltripeptide phosphatidylethanolamine (L-MTP-PE) on mice with alveolar echinococcosis and treated with albendazole.

Emília Dvoroznáková, Jarmila Porubcová, Viliam Snábel, Peter Fedorocko

Index: Parasitol. Res. 103(4) , 919-29, (2008)

Full Text: HTML

Abstract

The effect of liposomized muramyltripeptide phosphatidylethanolamine (L-MTP-PE) administered separately or with anthelmintic albendazole (ABZ) on cellular immunity of mice with alveolar echinococcosis was studied. The proliferative activity of splenic T and B lymphocytes was the most stimulated after combined L-MTP-PE + ABZ therapy [from weeks 8 to 14 post-infection (p.i.)] that also induced a long-term development of protective Th1 response (the highest serum concentration of IFN-gamma from weeks 8 to 18 p.i.). On the contrary, Th2 response (cytokine IL-5) in infected mice treated with L-MTP-PE was inhibited since week 8 p.i., but a significant long-term decrease in IL-5 concentration was found after combined L-MTP-PE+ABZ therapy until the end of the experiment (until week 26 p.i.). L-MTP-PE stimulated the production of superoxide anion (O2-) by peritoneal macrophages from weeks 8 to 12 p.i., but the highest O2- production was accordingly recorded after therapy L-MTP-PE+ABZ from weeks 8 to 18 p.i. Stimulation of cellular immunity of mice with alveolar echinococcis with L-MTP-PE and an interaction with ABZ's anti-parasitic effect resulted in the greatest and long-term reduction of growth of Echinococcus multilocularis cysts in the host from week 10 p.i. until the end of the experiment.


Related Compounds

  • Mifamurtide

Related Articles:

Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma.

2009-08-01

[Expert Rev. Anticancer Ther. 9(8) , 1035-49, (2009)]

In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells.

1999-04-01

[Cancer Biother. Radiopharm. 14(2) , 121-8, (1999)]

Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update.

1998-10-01

[Cancer Biother. Radiopharm. 13(5) , 363-8, (1998)]

Effect of MTP on TNF-alpha in perfused rat liver after bacteremia and ischemia/reperfusion.

1998-05-01

[J. Surg. Res. 76(2) , 179-84, (1998)]

Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.

2008-02-01

[Expert Rev. Anticancer Ther. 8(2) , 151-9, (2008)]

More Articles...